Omnes Capital's investments: arGEN-X

Entry Date 
Venture Capital


A new antibody platform targeting the treatment of cancer and autoimmune conditions

arGEN-X is a research-stage biopharmaceutical company with a broadly applicable, proprietary platform called SIMPLE Antibody™. Using this platform, arGEN-X is able to create a wide range of monoclonal antibody leads against a broad range of human disease targets. These antibodies are then given highly competitive properties using other technologies in many cases. The company has proven the benefits of its monoclonal antibody development platform by signing numerous partnerships and pursuing two proprietary clinical programmes.

Latest news